...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith Presentation at AACR Meeting April 10-15

I'd vote yes too but if there's no early deal in site then get us listed on the Naz ASAP.

No thanks.

- huge dilution
- 10s of millions of shares tied up for almost 8 years are not happy about and will likely try to exit
- IMO we're years away from anything that would get investors irrationally exuberant
- ZHCLF at 40 cents US tells us where we would sit

Share
New Message
Please login to post a reply